Royal Bank of Canada
GMAB icon

Royal Bank of Canada’s Genmab GMAB Stock Holding History

Royal Bank of Canada’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51M Sell
127,889
-22,246
-15% -$591K ﹤0.01% 2867
2026
Q1 		$4.03M Buy
150,135
+2,637
+2% +$79K ﹤0.01% 2576
2025
Q4 		$4.54M Buy
147,498
+31,406
+27% +$979K ﹤0.01% 2500
2025
Q3 		$3.56M Sell
116,092
-1,196
-1% -$29.1K ﹤0.01% 2929
2025
Q2 		$2.42M Sell
117,288
-3,277
-3% -$67.3K ﹤0.01% 3141
2025
Q1 		$2.36M Sell
120,565
-203,437
-63% -$4.27M ﹤0.01% 2827
2024
Q4 		$6.76M Sell
324,002
-473,811
-59% -$10.4M ﹤0.01% 2095
2024
Q3 		$19.4M Buy
797,813
+5,059
+0.6% +$135K ﹤0.01% 1363
2024
Q2 		$19.9M Buy
792,754
+8,382
+1% +$238K ﹤0.01% 1247
2024
Q1 		$23.5M Buy
784,372
+143,383
+22% +$4.21M 0.01% 1172
2023
Q4 		$20.4M Sell
640,989
-194,821
-23% -$6.12M ﹤0.01% 1277
2023
Q3 		$29.5M Buy
835,810
+118,762
+17% +$4.53M 0.01% 954
2023
Q2 		$27.3M Buy
717,048
+112,462
+19% +$4.48M 0.01% 1014
2023
Q1 		$22.8M Buy
604,586
+5,865
+1% +$225K 0.01% 1061
2022
Q4 		$25.4M Sell
598,721
-85,839
-13% -$3.54M 0.01% 1015
2022
Q3 		$22M Sell
684,560
-57,940
-8% -$2.03M 0.01% 1018
2022
Q2 		$24.1M Buy
742,500
+72,419
+11% +$2.35M 0.01% 996
2022
Q1 		$24.2M Buy
670,081
+24,996
+4% +$858K 0.01% 1126
2021
Q4 		$25.5M Buy
645,085
+21,755
+3% +$907K 0.01% 1238
2021
Q3 		$27.2M Buy
623,330
+38,585
+7% +$1.73M 0.01% 1125
2021
Q2 		$23.9M Buy
584,745
+54,420
+10% +$2.1M 0.01% 1210
2021
Q1 		$17.4M Sell
530,325
-57,302
-10% -$2.15M 0.01% 1368
2020
Q4 		$23.9M Buy
587,627
+54,683
+10% +$2.04M 0.01% 1134
2020
Q3 		$19.5M Buy
532,944
+67,597
+15% +$2.44M 0.01% 1089
2020
Q2 		$15.8M Sell
465,347
-35,285
-7% -$962K 0.01% 1176
2020
Q1 		$10.6M Buy
500,632
+49,116
+11% +$1.09M 0.01% 1287
2019
Q4 		$10.1M Buy
451,516
+27,299
+6% +$596K ﹤0.01% 1621
2019
Q3 		$8.6M Buy
+424,217
New +$8.36M ﹤0.01% 1675

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada's GMAB Position: Q2 2026 in Review

Royal Bank of Canada reduced its Genmab (GMAB) stake by 15% in Q2 2026, selling an estimated $591K and leaving 127,889 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2867.

Royal Bank of Canada first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $29.5M in Q3 2023. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Royal Bank of Canada held 127,889 shares of Genmab worth $3.51M as of Q2 2026.
  • Royal Bank of Canada sold 22,246 Genmab shares in Q2 2026, an estimated $591K.
  • Genmab made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #2867 holding.
  • Royal Bank of Canada first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • Royal Bank of Canada's Genmab position peaked at $29.5M in Q3 2023.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.